RxDoctor Payments Data

Rajah Fielder

Family · Carencro, LANPI 1033577838

Payments from drug & device makers

$422in general payments, 2019–2025

Across 26 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$173
  • Pfizer$71
  • Supernus Pharmaceuticals, Inc.$47
  • Neurocrine Biosciences, Inc.$35
  • Idorsia Pharmaceuticals US Inc$22
  • Tris Pharma Inc$17
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$422 in reported general payments places this provider in the 45th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,090
Medicare patients
73
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$50,018
OzempicSemaglutide26$25,284
XareltoRivaroxaban29$14,903
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$5,938
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine77$2,419
Doxepin Hcl20$1,911
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,705
Albuterol Sulfate HfaAlbuterol Sulfate40$1,653
Testosterone Cypionate32$1,459
Levothyroxine Sodium150$1,409
Lidocaine-PrilocaineLidocaine/Prilocaine13$1,264
Solifenacin Succinate11$1,209
Liothyronine Sodium33$970
Duloxetine Hcl43$951
Alprazolam204$890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieArmour Thyroid$17$48717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,610 family providers in Louisiana.

Other family in Carencro

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →